Luminous Therapeutics Corp.
Early-stage biotechnology company focused on self-amplifying RNA (saRNA) vaccines and RNA-based therapeutics for infectious and rare genetic diseases. The organization emphasizes saRNA platform development, targeted lipid-nanoparticle delivery to select organs (including nasal/mucosal routes), RNA base-editing approaches for transcript correction, and integrated CMC and manufacturing capabilities intended to enable large-scale, low-cost dose production and regulatory submissions.
Industries
N/A
Products
Pipeline of saRNA vaccine candidates and RNA-editing therapeutics
Portfolio of vaccine candidates for global infectious diseases and RNA-editing therapeutic programs for rare diseases, described as advancing across discovery, preclinical, and early clinical stages.
Pipeline of saRNA vaccine candidates and RNA-editing therapeutics
Portfolio of vaccine candidates for global infectious diseases and RNA-editing therapeutic programs for rare diseases, described as advancing across discovery, preclinical, and early clinical stages.
Services
saRNA vaccine and therapeutic development
End-to-end R&D for self-amplifying RNA vaccines and RNA-based therapeutics from discovery through preclinical evaluation.
LNP formulation and targeted delivery development
Formulation development to enable selective organ targeting, improved biodistribution, and tolerability for RNA cargo.
CMC, process development and manufacturing scale-up
CMC activities including process development, scale-up, and manufacturing in cGMP-compliant environments to support clinical and commercial supply.
Analytical characterization and release testing for RNA products
In-house analytical testing and characterization services to support product development and lot release for saRNA candidates.
Regulatory and quality systems support
Support for regulatory strategy and preparation of IND dossiers alongside implementation of quality management systems.
saRNA vaccine and therapeutic development
End-to-end R&D for self-amplifying RNA vaccines and RNA-based therapeutics from discovery through preclinical evaluation.
LNP formulation and targeted delivery development
Formulation development to enable selective organ targeting, improved biodistribution, and tolerability for RNA cargo.
CMC, process development and manufacturing scale-up
CMC activities including process development, scale-up, and manufacturing in cGMP-compliant environments to support clinical and commercial supply.
Analytical characterization and release testing for RNA products
In-house analytical testing and characterization services to support product development and lot release for saRNA candidates.
Regulatory and quality systems support
Support for regulatory strategy and preparation of IND dossiers alongside implementation of quality management systems.
Expertise Areas
- saRNA vaccine development
- RNA base-editing therapeutics
- Lipid nanoparticle formulation and targeted delivery
- cGMP manufacturing and CMC process development
Key Technologies
- Self-amplifying RNA (saRNA)
- Lipid nanoparticle (LNP) delivery
- ADAR-mediated A-to-I RNA base editing
- Nasal/mucosal vaccine delivery formulations